{
  "abstract": "Glofitamab, a CD20×CD3 bispecific antibody, has shown durable activity in relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL), but real-world data from Korean patients and after CAR-T failure remain limited. We retrospectively analyzed 46 patients with RR-DLBCL treated with glofitamab monotherapy. Response and safety were assessed in all patients, whereas the main survival and prognostic analyses were conducted in the non-bridge-intent cohort (n = 41), excluding five bridge-intent patients. Median age was 57.5 years; patients had received a median of three prior lines, and 58.7% had failed prior CAR-T. In the overall cohort, the objective response rate was 39.1% and the complete response rate was 32.6%. In the non-bridge-intent cohort, median progression-free survival (PFS) and overall survival (OS) were 2.6 and 5.9 months, respectively, after a median follow-up of 8.2 months. Median duration of response was not reached, and 10 of 15 responders remained in response. Prior CAR-T exposure was not associated with PFS or OS. A longer pre-glofitamab interval was associated with improved PFS (adjusted hazard ratio 0.51 per category increase; p = 0.018), but not OS. Patients with an interval < 1 month had an ORR of 15.4% and median PFS of 1.0 month. Cytokine release syndrome occurred in 26.1%, all Grade 1 or 2; no immune effector cell-associated neurotoxicity syndrome or treatment-related deaths occurred. Glofitamab monotherapy demonstrated clinically meaningful activity and manageable safety in heavily pretreated RR-DLBCL. In exploratory analyses, a shorter pre-glofitamab treatment interval was associated with poorer outcomes; this hypothesis-generating observation requires prospective validation.",
  "abstract_shown": true,
  "affiliations": [
    "Division of Hematology and Oncology, Department of Internal Medicine, Korea University College of Medicine, 73, Goryeodae-ro Seongbuk-gu, Seoul, 02841, Republic of Korea.",
    "Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, 03080, Republic of Korea.",
    "Department of Hematology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, 07345, Republic of Korea.",
    "Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 06591, Seoul, Republic of Korea.",
    "Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro Gangnam-gu, Seoul, 06351, Republic of Korea.",
    "Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro Gangnam-gu, Seoul, 06351, Republic of Korea. starload0326@gmail.com."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 7,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Changgon Kim"
    },
    {
      "affs": [
        1
      ],
      "name": "Youngil Koh"
    },
    {
      "affs": [
        2
      ],
      "name": "Youngwoo Jeon"
    },
    {
      "affs": [
        0,
        3
      ],
      "name": "Yoon Seok Choi"
    },
    {
      "affs": [
        4
      ],
      "name": "Seok Jin Kim"
    },
    {
      "affs": [
        4
      ],
      "name": "Won Seog Kim"
    },
    {
      "affs": [
        5
      ],
      "name": "Sang Eun Yoon"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/ddkv891d52tvn.bib",
  "cited_by": 0,
  "doi": "10.1007/s00277-026-07212-9",
  "fulltext_url": "https://europepmc.org/articles/PMC13719715",
  "id": "ddkv891d52tvn",
  "issns": [
    "0939-5555",
    "1432-0584"
  ],
  "landing_url": "https://europepmc.org/article/MED/42955341",
  "language": "eng",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Research"
    ],
    [
      "openalex",
      "2734|Lymphoma Diagnosis and Treatment"
    ]
  ],
  "openalex": "W7172137558",
  "pdf_url": "https://europepmc.org/articles/PMC13719715?pdf=render",
  "pmcid": "PMC13719715",
  "pmid": "42955341",
  "published": "2026-08-01",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/ddkv891d52tvn.ris",
  "sources": [
    {
      "first_seen": "2026-10-31T12:21:29Z",
      "native_id": "MED:42955341",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42955341"
    },
    {
      "first_seen": "2026-11-02T12:23:38Z",
      "native_id": "PMC13719715",
      "source": "pmc",
      "url": "https://doi.org/10.1007/s00277-026-07212-9"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2734|Lymphoma Diagnosis and Treatment",
      "subfield": "general"
    }
  ],
  "title": "Real-world outcomes of glofitamab monotherapy in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma: A multicenter Korean cohort.",
  "title_text": "Real-world outcomes of glofitamab monotherapy in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma: A multicenter Korean cohort.",
  "type": "peer-reviewed",
  "updated_at": "2026-11-03T12:20:44Z",
  "url": "https://research.draconitic.com/paper/ddkv891d52tvn",
  "venue": "Annals of hematology",
  "versions": []
}